NCT04990869View on ClinicalTrials.gov

Inflammation in COPD and the Effect of Nicotinamide Riboside

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions
COPD
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.

DIETARY_SUPPLEMENT

Placebo

Placebo

Trial Locations (1)

Unknown

Respiratory Research Unit, Bispebjerg Hospital, Copenhagen

Sponsors

Collaborators (1)

Elysium Health
All Listed Sponsors
collaborator

Bispebjerg Hospital

OTHER

collaborator

Elysium Health

INDUSTRY

lead

University of Copenhagen

OTHER

NCT04990869 - Inflammation in COPD and the Effect of Nicotinamide Riboside | Biotech Hunter | Biotech Hunter